MATTHEW SCHACHTERLE: Open Payments
NPI 1376140335 · SURPRISE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,568 in 85 payments from 20 companies in 2025. Trend: 2023 $214 · 2024 $1,230 · 2025 $1,568
Food & beverage: $1,568
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $378 |
| AstraZeneca Pharmaceuticals LP | 9 | $192 |
| Novo Nordisk Inc | 9 | $155 |
| GlaxoSmithKline, LLC. | 6 | $119 |
| PFIZER INC. | 6 | $113 |
| Astellas Pharma US Inc | 4 | $82 |
| Viatris Specialty LLC | 5 | $79 |
| Lilly USA, LLC | 5 | $78 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $63 |
| Eisai Inc. | 2 | $55 |
Products named: VRAYLAR, AIRSUPRA, TRELEGY ELLIPTA, Ozempic, QULIPTA, NURTEC ODT, Veozah, YUPELRI.
Industry payments across AZ — which companies pay providers there.
